Quarterly report [Sections 13 or 15(d)]

Acquisitions - Kinnate Acquisition (Details)

v3.25.3
Acquisitions - Kinnate Acquisition (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2025
Apr. 30, 2024
Sep. 30, 2025
Sep. 30, 2025
Dec. 31, 2024
Asset acquisition          
Exarafenib milestone contingent consideration     $ 3,500 $ 3,500 $ 3,214
CVR Agreement | Kinnate CVR holders          
Asset acquisition          
Exarafenib milestone contingent consideration   $ 3,200 3,500 3,500  
Kinnate          
Asset acquisition          
Asset acquisition, share price (in dollars per share)   $ 2.5879      
Total purchase consideration   $ 126,400      
Reduction to gain on acquisition     1,700    
Asset acquisition reduction to prepaid expenses and other current assets     300    
Asset acquisition reduction to other assets long term     1,000    
Asset acquisition reduction to general and administrative expenses     400    
Kinnate | Kinnate CVR holders          
Asset acquisition          
Contingent consideration       600  
Contingent consideration liability, current     $ 600 $ 600  
Kinnate | CVR Agreement | Kinnate CVR holders          
Asset acquisition          
Percentage share from potential milestone 100.00%        
Cash received from milestone payments $ 30,500